Participants must have relapsed and refractory multiple myeloma (RRMM) with measurable disease
Participants must have received at least 3 prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and CD38-directed monoclonal antibody
Participants must have an Eastern Cooperative Group (ECOG) performance status of 0-1
Participants must have acceptable laboratory values as defined by the protocol
You may not be if
Participants must not have known central nervous system (CNS) involvement with myeloma
Participants cannot have plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, and skin changes) syndrome, or primary light chain amyloidosis
Participants cannot have ongoing acute systemic infection requiring antimicrobial therapy
Participants cannot require systemic steroids for any condition
